Braidwell LP
- SEC CIK
- 0001920938
- Latest filing
- Aug 14, 2026
Holdings in Q1 2025
Holdings as of Mar 31, 2025, filed May 15, 2025. Long positions only; changes compare share counts with Q4 2024.
- Positions
- 64
- −9 vs. Q4 2024
- Portfolio value
- $2.84B
- −$527.8M (−15.7%) vs. Q4 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| TRVITrevi Therapeutics, Inc. | COM | 72,083 | $453.4K | <0.1% | +72,083 | New | History |
| SKYESkye Bioscience, Inc. | COM NEW | 825,732 | $1.31M | <0.1% | 00.0% | Unchanged | History |
| BBNXBeta Bionics, Inc. | COM | 140,000 | $1.71M | 0.1% | +140,000 | New | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 2,472,806 | $3.19M | 0.1% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM | 1,440,499 | $3.62M | 0.1% | 00.0% | Unchanged | History |
| AARDAardvark Therapeutics, Inc. | COM | 500,000 | $3.75M | 0.1% | +500,000 | New | History |
| MTSRMetsera, Inc. | COM | 175,000 | $4.76M | 0.2% | +175,000 | New | History |
| LUNGPulmonx Corp | COM | 752,541 | $5.06M | 0.2% | 00.0% | Unchanged | History |
| Alphatec Hldgs Inc02081GAB8 | NOTE 0.750% 8/0 | – | $5.79M | 0.2% | – | – | – |
| DNTHDianthus Therapeutics, Inc. | COM | 375,355 | $6.81M | 0.2% | −831,234−68.9% | Reduced | History |
| CSTLCastle Biosciences Inc | COM | 365,247 | $7.31M | 0.3% | +365,247 | New | History |
| CGEMCullinan Therapeutics, Inc. | COM | 980,773 | $7.42M | 0.3% | −195,400−16.6% | Reduced | History |
| CELCCelcuity Inc. | COM | 884,306 | $8.94M | 0.3% | 00.0% | Unchanged | History |
| IRWDIronwood Pharmaceuticals Inc | COM CL A | 6,622,584 | $9.74M | 0.3% | +1,182,307+21.7% | Added | History |
| RGENRepligen Corp | COM | 81,656 | $10.4M | 0.4% | −202,167−71.2% | Reduced | History |
| REPLReplimune Group, Inc. | COM | 1,461,826 | $14.3M | 0.5% | −15,276−1.0% | Reduced | History |
| SRPTSarepta Therapeutics, Inc. | COM | 234,500 | $15.0M | 0.5% | −130,400−35.7% | Reduced | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 48,690 | $16.1M | 0.6% | +48,690 | New | History |
| ORKAOruka Therapeutics, Inc. | COM | 1,572,426 | $16.1M | 0.6% | +424,750+37.0% | Added | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 106,713 | $16.6M | 0.6% | +106,713 | New | History |
| XNCRXencor Inc | COM | 1,655,690 | $17.6M | 0.6% | +1,040,159+169.0% | Added | History |
| Dexcom Inc252131AK3 | NOTE 0.250%11/1 | – | $18.0M | 0.6% | – | – | – |
| MRVIMaravai Lifesciences Holdings, Inc. | COM CL A | 8,353,287 | $18.5M | 0.6% | 00.0% | Unchanged | History |
| Dexcom Inc252131AM9 | NOTE 0.375% 5/1 | – | $22.8M | 0.8% | – | – | – |
| HROWHarrow, Inc. | COM | 956,839 | $25.5M | 0.9% | +49,800+5.5% | Added | History |
| KIDSOrthopediatrics Corp | COM | 1,107,770 | $27.3M | 1.0% | 00.0% | Unchanged | History |
| DAWNDay One Biopharmaceuticals, Inc. | Stock | 3,536,853 | $28.0M | 1.0% | −1,337,000−27.4% | Reduced | History |
| BCAXBicara Therapeutics Inc. | COM | 2,162,803 | $28.2M | 1.0% | +162,144+8.1% | Added | History |
| PENPenumbra Inc | COM | 110,128 | $29.4M | 1.0% | −73,700−40.1% | Reduced | History |
| VKTXViking Therapeutics, Inc. | COM | 1,435,955 | $34.7M | 1.2% | −43,711−3.0% | Reduced | History |
| ADPTAdaptive Biotechnologies Corp | COM | 4,803,794 | $35.7M | 1.3% | +4,803,794 | New | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 1,652,334 | $36.1M | 1.3% | −446,532−21.3% | Reduced | History |
| DYNDyne Therapeutics, Inc. | COM | 3,621,344 | $37.9M | 1.3% | +2,940,162+431.6% | Added | History |
| BPMCBlueprint Medicines Corp | COM | 439,968 | $38.9M | 1.4% | +439,968 | New | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 2,578,404 | $41.6M | 1.5% | 00.0% | Unchanged | History |
| ATECAlphatec Holdings, Inc. | COM NEW | 4,259,429 | $43.2M | 1.5% | +2,939+0.1% | Added | History |
| ISRGIntuitive Surgical Inc | COM NEW | 88,000 | $43.6M | 1.5% | +12,700+16.9% | Added | History |
| KNSAKiniksa Pharmaceuticals International, plc | ORD SHS CL A | 1,962,909 | $43.6M | 1.5% | −1,489,538−43.1% | Reduced | History |
| Immunocore Hldgs PLC45258DAB1 | NOTE 2.500% 2/0 | – | $43.8M | 1.5% | – | New | – |
| BridgeBio Pharma, Inc.10806XAD4 | NOTE 2.250% 2/0 | – | $43.8M | 1.5% | – | – | – |
| INSPInspire Medical Systems, Inc. | COM | 302,410 | $48.2M | 1.7% | +9,000+3.1% | Added | History |
| EWTXEdgewise Therapeutics, Inc. | COM | 2,458,808 | $54.1M | 1.9% | +126,612+5.4% | Added | History |
| GHGuardant Health, Inc. | COM | 1,327,327 | $56.5M | 2.0% | −1,520,604−53.4% | Reduced | History |
| TMDXTransMedics Group, Inc. | COM | 854,884 | $57.5M | 2.0% | −67,216−7.3% | Reduced | History |
| APGEApogee Therapeutics, Inc. | COM | 1,540,362 | $57.5M | 2.0% | 00.0% | Unchanged | History |
| IRTCiRhythm Holdings, Inc. | COM | 556,391 | $58.2M | 2.0% | −149,000−21.1% | Reduced | History |
| NUVLNuvalent, Inc. | COM | 840,945 | $59.6M | 2.1% | +599,710+248.6% | Added | History |
| GKOSGLAUKOS Corp | COM | 624,435 | $61.5M | 2.2% | +335,559+116.2% | Added | History |
| DHRDanaher Corp | Stock | 309,339 | $63.4M | 2.2% | +309,339 | New | History |
| TMOThermo Fisher Scientific Inc. | Stock | 127,733 | $63.6M | 2.2% | +37,979+42.3% | Added | History |
| BridgeBio Pharma, Inc.10806XAB8 | NOTE 2.500% 3/1 | – | $72.0M | 2.5% | – | – | – |
| KRYSKrystal Biotech, Inc. | COM | 400,744 | $72.3M | 2.5% | +200,244+99.9% | Added | History |
| CGONCG Oncology, Inc. | COM | 3,283,317 | $80.4M | 2.8% | 00.0% | Unchanged | History |
| Ironwood Pharmaceuticals Inc46333XAH1 | NOTE 1.500% 6/1 | – | $82.5M | 2.9% | – | – | – |
| ALGNAlign Technology Inc | COM | 530,530 | $84.3M | 3.0% | +155,351+41.4% | Added | History |
| Neogenomics Inc64049MAB6 | NOTE 0.250% 1/1 | – | $87.9M | 3.1% | – | – | – |
| iRhythm Holdings, Inc.450056AB2 | NOTE 1.500% 9/0 | – | $89.7M | 3.2% | – | New | – |
| XENEXenon Pharmaceuticals Inc. | COM | 2,709,875 | $90.9M | 3.2% | −204,089−7.0% | Reduced | History |
| ARGXArgenx SE | SPONSORED ADR | 160,849 | $95.2M | 3.3% | +80,083+99.2% | Added | History |
| Repligen Corp759916AD1 | NOTE 1.000%12/1 | – | $95.8M | 3.4% | – | – | – |
| LEGNLegend Biotech Corp | SPONSORED ADS | 2,977,951 | $101.0M | 3.6% | 00.0% | Unchanged | History |
| NBIXNeurocrine Biosciences Inc | Stock | 1,191,925 | $131.8M | 4.6% | +290,135+32.2% | Added | History |
| NovoCure Ltd67011XAB9 | NOTE 11/0 | – | $136.6M | 4.8% | – | – | – |
| Guardant Health, Inc.40131MAD1 | DEBT 1.250% 2/1 | – | $227.4M | 8.0% | – | New | – |
Sold out since Q4 2024 (22)
Positions held at the end of Q4 2024 that are gone from this filing.
| Security | Class | Shares in Q4 2024 | Value in Q4 2024 | % of portfolio in Q4 2024 | History |
|---|---|---|---|---|---|
| Guardant Health, Inc.40131MAB5 | NOTE 11/1 | – | $226.0M | 6.7% | – |
| Nuvasive Inc670704AJ4 | NOTE 0.375% 3/1 | – | $113.2M | 3.4% | – |
| AVDLAvadel Pharmaceuticals PLC | Stock | 4,105,726 | $43.2M | 1.3% | History |
| FNAParagon 28, Inc. | COM | 3,834,809 | $39.6M | 1.2% | History |
| BNTXBioNTech SE | SPONSORED ADS | 309,865 | $35.3M | 1.0% | History |
| KROSKeros Therapeutics, Inc. | COM | 1,894,439 | $30.0M | 0.9% | History |
| IMTXImmatics N.V. | SHS | 3,503,965 | $24.9M | 0.7% | History |
| GERNGeron Corp | COM | 7,006,315 | $24.8M | 0.7% | History |
| BRKRBruker Corp | COM | 353,200 | $20.7M | 0.6% | History |
| EXASExact Sciences Corp | COM | 353,000 | $19.8M | 0.6% | History |
| PCVXVaxcyte, Inc. | COM | 222,424 | $18.2M | 0.5% | History |
| Amphastar Pharmaceuticals IN03209RAB9 | NOTE 2.000% 3/1 | – | $16.3M | 0.5% | – |
| JSPRJasper Therapeutics, Inc. | COM NEW | 714,658 | $15.3M | 0.5% | History |
| CADLCandel Therapeutics, Inc. | COM | 1,600,000 | $13.9M | 0.4% | History |
| RCUSArcus Biosciences, Inc. | COM | 802,100 | $11.9M | 0.4% | History |
| FDMT4D Molecular Therapeutics, Inc. | COM | 1,225,448 | $6.83M | 0.2% | History |
| NVRONevro Corp | COM | 1,698,768 | $6.32M | 0.2% | History |
| CBLLCeribell, Inc. | COM | 210,000 | $5.43M | 0.2% | History |
| Cutera Inc232109AG3 | NOTE 4.000% 6/0 | – | $2.61M | 0.1% | – |
| Cutera Inc232109AD0 | NOTE 2.250% 6/0 | – | $2.27M | 0.1% | – |
| PTGXProtagonist Therapeutics, Inc | COM | 20,109 | $776.2K | <0.1% | History |
| VRDNViridian Therapeutics, Inc. | COM | 34,094 | $653.6K | <0.1% | History |